Welcome to our dedicated page for ILLUMINA SEC filings (Ticker: ILMN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Illumina SEC filings document the company’s genomics technology business, financial results, governance and capital actions. Form 8-K reports cover quarterly and annual operating results, preliminary financial updates, share repurchase authorization, management and board changes, and Regulation FD disclosures.
The filing record also includes definitive proxy materials for annual meeting matters, director elections, compensation and shareholder voting. Material-event filings document completed acquisition activity, including the purchase of SomaLogic and Sengenics aptamer-based and functional proteomics assets, along with exhibits, common-stock repurchase disclosures and other capital-structure records.
ILLUMINA, INC. (ILMN) director Keith A. Meister reported indirect open-market sales totaling 263,560 shares of Illumina common stock on September 2–4, 2026, for private investment funds advised by Corvex Management LP. The sales were executed at reported weighted average prices including $213.20, $215.20, $218.39 and $221.55 per share. Corvex and Mr. Meister disclaim beneficial ownership of the funds’ holdings except to the extent of their pecuniary interest. No Rule 10b5-1 trading plan is reported, and Mr. Meister is shown with 6,780 shares held directly as of September 2, 2026.
ILLUMINA, INC. (ILMN) received a Rule 144 notice from Corvex Management, an affiliate of a company director, for a proposed sale of 150,000 shares of common stock through Goldman Sachs & Co. LLC on the Nasdaq Stock Market. The proposed sale has an aggregate market value of $31,987,500. Illumina common shares outstanding are listed as 151,000,000 as of the notice; this is a baseline figure, not the amount being sold. In the three months before the notice, Corvex reported multiple open-market sales of Illumina shares on various August and September 2026 dates.
ILLUMINA, INC. (ILMN) director Keith A. Meister reported indirect sales of 375,941 shares of Illumina common stock on August 25–27, 2026. The shares were sold by Corvex-managed investment funds at weighted average prices from about $225.26 to $231.23 per share. Meister and Corvex disclaim beneficial ownership beyond their pecuniary interests. He also reports 6,780 shares held directly.
ILLUMINA, INC. (ILMN) is the issuer for which Corvex Management filed a notice under Rule 144 to sell common stock. Corvex, an affiliate of a director, plans to sell up to 200,000 shares of Illumina common stock through Goldman Sachs & Co. LLC, with an aggregate market value of $44,968,000, on or after August 27, 2026, on the Nasdaq Stock Market. Illumina had 151,000,000 shares outstanding of common stock for context. Corvex states it may be deemed the beneficial owner of shares held by funds it advises, and that the shares to be sold were purchased in various open market transactions between October 25, 2023 and March 27, 2025. The notice also lists multiple prior sales of Illumina shares by Corvex-managed entities during the past three months.
ILLUMINA, INC. (ILMN) is the issuer of common stock that an investment fund advised by Corvex Management, an affiliate of an Illumina director, plans to sell under Rule 144. The planned sale covers 300,000 shares of common stock, with an aggregate market value of $66,966,000.00, to be executed through Goldman Sachs & Co. LLC. Illumina reports 151,000,000 shares outstanding of this class as of the notice, which is a baseline figure, not the amount being sold.
Corvex-linked entities have reported multiple sales of Illumina common stock in the past three months, including 220,000 shares on May 28, 2026 for $34,686,783.32 and 457,858 shares on August 4, 2026 for $91,616,949.73. The shares now to be sold were purchased in various open market transactions between October 25, 2023 and March 27, 2025.
ILLUMINA, INC. (ILMN) director Keith A. Meister, through private investment funds advised by Corvex Management LP, reported indirect open‑market sales of a total of 679,574 shares of Illumina common stock on August 19–21, 2026, across multiple trades at weighted average prices within ranges from $201.59 to $220.43 per share. Corvex and Mr. Meister each disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest. A separate holding entry shows 6,780 shares of Illumina common stock held directly.
ILLUMINA, INC. (ILMN) received a notice that Corvex Management, an affiliate of an Illumina director, has filed to sell 250,000 shares of Illumina common stock under Rule 144. The shares are to be sold through Goldman Sachs & Co. LLC, with an aggregate market value of $53,310,000.00 and Illumina having 151,000,000 shares outstanding. The shares to be sold were purchased in various open market transactions between October 25, 2023 and March 27, 2025. Corvex has also reported multiple sizeable Illumina share sales over the past three months.
ILLUMINA, INC. (ILMN) executive Jakob Wedel Christensen, SVP, Strategy/Corp Development, reported selling 1,033 shares of common stock on 2026-08-18 at $191.52 per share in an open-market or private transaction. After this trade, he directly holds 14,023 shares. The transaction was affirmed as made under a Rule 10b5-1 trading plan.
ILLUMINA, INC. (ILMN) has a notice under Rule 144 for a planned resale of its Common Stock by Corvex Management, an affiliate of Illumina director Keith Meister. Corvex indicates an intent to sell 355,000 shares, with an aggregate market value of approximately $72,775,000, through Goldman Sachs & Co. LLC after 08/20/2026.
Corvex also reports prior open-market sales over the past three months totaling several hundred thousand Illumina shares across multiple transactions.
Illumina, Inc. (ILMN) received a Rule 144 notice from Jakob Wedel covering a planned sale of its common stock. The notice lists 1,033 shares of common stock to be sold through Morgan Stanley Smith Barney LLC, with an aggregate value of $199,508.46, and references trading on NDAQ. The securities to be sold include shares underlying Restricted Stock Units with a listed date of 02/17/2026, and a proposed sale date of 08/18/2026.